



PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Samuel F. Hunter, M.D.
For: Method for Treatment of Demyelinating Central Nervous System
Disease
Filing Date: October 16, 2003
Group Art Unit: 1646
Examiner: Not yet assigned
Attorney's Docket No. 11918N/021452
Customer No.: 32885

Serial No. : 10/687,576

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(SUBMISSION BEFORE MAILING DATE OF A FIRST ACTION ON THE MERITS)

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 15, 2004

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and §1.98, applicants hereby submit an Information Disclosure Statement for consideration by the Examiner.

I. List of Patents, Publications or Other Information

The Patents, publications, or other information submitted for consideration by the Office are listed below and on the PTO-1449(s), attached hereto.

II. Copies

The Patents and other publications listed on the attached Form PTO-1449 are in the English language or an English language abstract is provided.

The application was filed on October 16, 2003. In view of the waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) published in the Official Gazette on August 5, 2003, for applications filed after June 30, 2003, copies of the cited U.S. Patents are not attached. A copy of WO 00/77028 A1 and WO 02/13862 A2 is provided.

III. Concise Explanation of Relevance

The attached documents, publications, and/or other information attached hereto are in the English language or a translation is provided. Thus, a statement of relevancy is not required.

IV. Fees


The IDS is being filed under 37 C.F.R. §1.97(b); before mailing date of a first action on the merits, whichever event occurs last. No fee or statement is required.

V. Payment of Fees

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned.

Respectfully submitted,


Richard S. Myers, Jr.
Registration No. 42,022
STITES & HARBISON PLLC
424 Church Street, Suite 1800
SunTrust Center
Nashville, TN 37219-2376
(615) 244-5200
Customer No. 32885

Attorney for Applicant



SERIAL NO. 10/687,576


CERTIFICATE OF FIRST CLASS MAILING


I hereby certify that this Supplemental Information Disclosure Statement, Form PTO-1449, Prior Art References, and Return Receipt Postcard are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on June 15, 2004.

Richard S. Myers, Jr.


Registration No. 42,072


Date

11918N:021452:583953:1:NASHVILLE

Comparable to Form PTO-1449		U.S. Department of Commerce Patent & Trademark Office		Atty. Docket No. 11918N/021452		Serial No. 10/687,576		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Customer No. 32885				
				Applicant				
				Samuel F. Hunter				
				Filing Date October 16, 2003		Group 1646		
Examiner Initial		Document No.	Date	Name		Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS								
		Document No.	Date	Name	Class	Subclass	Translation	
							Yes	No
MISCELLANEOUS DOCUMENTS								
		MCQUALTER, et al.; <u>Granulocyte Macrophage Colony-Stimulating Factor: A New Putative Therapeutic Target in Multiple Sclerosis</u> ; Journal of Experimental Medicine, Tokyo, JP; Vol. 194; No. 7; 1 October 2001; pp. 873-881.						
		SMITH, et al.; <u>Macrophage and Microglial Responses to Cytokines In Vitro: Phagocytic Activity, Proteolytic Enzyme Release, and Free Radical Production</u> ; Journal of Neuroscience Research; Vol. 54; No. 1; 1 October 1998; pp. 68-78.						
		ZAVALA, et al.; <u>G-CSF Therapy of Ongoing Experimental Allergic Encephalomyelitis Via Chemokine- and Cytokine-Based Immune Deviation</u> ; The Journal of Immunology; Vol. 168; No. 4; 15 February 2002; pp. 2011-2019.						
Examiner:		Date Considered						
<p>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								